Although neurocognitive deficit is the best-recognized indicator of Alzheimer’s disease (AD), psychotic and other noncognitive symptoms are the prime cause of institutionalization. BACE1 is the rate-limiting enzyme in the production of Aβ of AD, and one of the promising therapeutic targets in countering cognitive decline and amyloid pathology. Changes in BACE1 activity have also emerged to cause significant noncognitive neuropsychiatric symptoms and impairments of circadian rhythms, as evident from clinical trials and reports in transgenic models. In this study, we consider key characteristics of BACE1 with its contribution to neurocognitive deficit and other psychiatric symptoms of AD. We argue that a growing list of noncognitive mental impairments related to pharmacological modulation of BACE1 might present a major obstacle in clinical translation of emerging therapeutic leads targeting this protease. The adverse effects of BACE1 inhibition on mental health call for a revision of treatment strategies that assume indiscriminate inhibition of this key protease, and stress the need for further mechanistic and translational studies.
Alzheimer’s Association Calcium Hypothesis Workgroup. 2017. Calcium hypothesis of Alzheimer’s disease and brain aging: a framework for integrating new evidence into a comprehensive theory of pathogenesis. Alzheimers Dement13(2):178–82.e17.
2.
ArispeNRojasEPollardHB. 1993. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A90(2):567–71.
3.
AsheKHZahsKR. 2010. Probing the biology of Alzheimer’s disease in mice. Neuron66(5):631–45.
4.
AshleyDJ. 1989. The physiology of excitable cells. New York: Cambridge University Press.
5.
BaraoSMoecharsDLichtenthalerSFDe StrooperB.2016. BACE1 physiological functions may limit its use as therapeutic target for Alzheimer’s disease. Trends Neurosci39(3):158–69.
6.
BaratchiSEvansJTateWPAbrahamWCConnorB.2012. Secreted amyloid precursor proteins promote proliferation and glial differentiation of adult hippocampal neural progenitor cells. Hippocampus22(7):1517–27.
7.
BenjannetSElagozAWickhamLMamarbachiMMunzerJSBasakA, and others. 2001. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem276(14):10879–87.
8.
BennettBDDenisPHaniuMTeplowDBKahnSLouisJC, and others. 2000. A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer’s beta -secretase. J Biol Chem275(48):37712–7.
9.
BezanillaF. 2008. Ion channels: from conductance to structure. Neuron60(3):456–68.
10.
BoerboomADionVChariotAFranzenR.2016. Molecular mechanisms involved in Schwann cell plasticity. Front Mol Neurosci10:38.
11.
CannonWB. 1939. The wisdom of the body. New York: W.W. Norton & Company.
12.
CapellASteinerHWillemMKaiserHMeyerCWalterJ, and others. 2000. Maturation and pro-peptide cleavage of beta-secretase. J Biol Chem275(40):30849–54.
13.
CastellaniRJPlascencia-VillaGPerryG.2019. The amyloid cascade and Alzheimer’s disease therapeutics: theory versus observation. Lab Invest99(7):958–70.
14.
ChasseigneauxSDincLRoseCChabretCCoulpierFTopilkoP, and others. 2011. Secreted amyloid precursor protein beta and secreted amyloid precursor protein alpha induce axon outgrowth in vitro through Egr1 signaling pathway. PLoS One6(1):e16301.
15.
Chavarria-SilesIWhiteTde LeeuwCGoudriaanALipsEEhrlichS, and others. 2016. Myelination-related genes are associated with decreased white matter integrity in schizophrenia. Eur J Hum Genet24(3):381–6.
16.
ChenYJJohnsonMALiebermanMDGoodchildRESchobelSLewandowskiN, and others. 2008. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci28(27):6872–83.
17.
ColeSLVassarR.2008. BACE1 structure and function in health and Alzheimer’s disease. Curr Alzheimer Res5(2):100–20.
18.
De StrooperB. 2010. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev90(2):465–94.
19.
DeWittDEHirschIB. 2003. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA289(17):2254–64.
20.
EganMFKostJVossTMukaiYAisenPSCummingsJL, and others. 2019a. randomized trial of verubecestat for prodromal Alzheimer’s disease. N Engl J Med380(15):1408–20.
21.
EganMFMukaiYVossTKostJStoneJFurtekC, and others. 2019b. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease. Alzheimers Res Ther11(1):68.
22.
EggertSPaligaKSobaPEvinGMastersCLWeidemannA, and others. 2004. The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem279(18):18146–56.
FilserSOvsepianSVMasanaMBlazquez-LlorcaLBrandt ElvangAVolbrachtC, and others. 2015. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry77(8):729–39.
25.
FlynnDDFerrari-DiLeoGMashDCLeveyAI. 1995. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer’s disease. J Neurochem64(4):1888–91.
26.
FormanMPalczaJTsengJStoneJAWalkerBSwearingenD, and others. 2019. Safety, tolerability, and pharmacokinetics of the beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor verubecestat (MK-8931) in healthy elderly male and female subjects. Clin Transl Sci12(5):545–55.
27.
FurukawaKBargerSWBlalockEMMattsonMP. 1996. Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature379(6560):74–78.
28.
GersbacherMTKimDYBhattacharyyaRKovacsDM. 2010. Identification of BACE1 cleavage sites in human voltage-gated sodium channel beta 2 subunit. Mol Neurodegener5:61.
29.
GuZJiangQFuAKIpNYYanZ.2005. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci25(20):4974–84.
30.
HaassCSelkoeDJ. 1993. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell75(6):1039–42.
31.
HaassCSelkoeDJ. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol8(2):101–12.
32.
HabibASawmillerDTanJ.2017. Restoring soluble amyloid precursor protein alpha functions as a potential treatment for Alzheimer’s disease. J Neurosci Res95(4):973–91.
33.
HampelHVassarRDe StrooperBHardyJWillemMSinghN, and others. 2020. The beta-secretase BACE1 in Alzheimer’s disease. Biol Psychiatry. Epub Feb 13. doi:10.1016/j.biopsych.2020.02.001
34.
HaniuMDenisPYoungYMendiazEAFullerJHuiJO, and others. 2000. Characterization of Alzheimer’s beta-secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem275(28):21099–106.
35.
HavelPJ. 2002. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol13(1):51–9.
36.
HenleyDRaghavanNSperlingRAisenPRamanRRomanoG.2019. Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease. N Engl J Med380(15):1483–5.
37.
HuXHeWDiaconuCTangXKiddGJMacklinWB, and others. 2008. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J22(8):2970–80.
38.
HuXHicksCWHeWWongPMacklinWBTrappBD, and others. 2006. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci9(12):1520–5.
39.
IarkovABarretoGEGrizzellJAEcheverriaV.2020. Strategies for the treatment of Parkinson’s disease: beyond dopamine. Front Aging Neurosci12:4.
40.
ImbimboBPPomaraN.2019. Drug-induced reductions in brain amyloid-beta levels may adversely affect cognition and behavior by a disruption of functional connectivity homeostasis. Neurodegener Dis Manag9(4):189–91.
41.
JonssonTAtwalJKSteinbergSSnaedalJJonssonPVBjornssonS, and others. 2012. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature488(7409):96–9.
42.
KandalepasPCSadleirKREimerWAZhaoJNicholsonDAVassarR.2013. The Alzheimer’s beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol126(3):329–52.
43.
KangDEPietrzikCUBaumLChevallierNMerriamDEKounnasMZ, and others. 2000. Modulation of amyloid beta-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest106(9):1159–66.
44.
KangELCameronANPiazzaFWalkerKRTescoG.2010. Ubiquitin regulates GGA3-mediated degradation of BACE1. J Biol Chem285(31):24108–19.
45.
KesbyJPEylesDWMcGrathJJScottJG. 2018. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry8(1):30.
46.
KhachaturianZS. 1994. Calcium hypothesis of Alzheimer’s disease and brain aging. Ann N Y Acad Sci747:1–11.
47.
KimDYCareyBWWangHInganoLABinshtokAMWertzMH, and others. 2007. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol9(7):755–64.
KitazumeSSaidoTCHashimotoY.2003. Alzheimer’s beta-secretase cleaves a glycosyltransferase as a physiological substrate. Glycoconj J20(1):59–62.
50.
KotasMEMedzhitovR.2015. Homeostasis, inflammation, and disease susceptibility. Cell160(5):816–27.
51.
LairdFMCaiHSavonenkoAVFarahMHHeKMelnikovaT, and others. 2005. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci25(50):11693–709.
52.
LazarevicVFienkoSAndres-AlonsoMAnniDIvanovaDMontenegro-VenegasC, and others. 2017. Physiological concentrations of amyloid beta regulate recycling of synaptic vesicles via alpha7 acetylcholine receptor and CDK5/calcineurin signaling. Front Mol Neurosci10:221.
53.
LiQSudhofTC. 2004. Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J Biol Chem279(11):10542–50.
54.
LichtenthalerSFDominguezDWestmeyerGGReissKHaassCSaftigP, and others. 2003. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem278(49):48713–9.
55.
LiuYFordBMannMAFischbachGD. 2001. Neuregulins increase alpha7 nicotinic acetylcholine receptors and enhance excitatory synaptic transmission in GABAergic interneurons of the hippocampus. J Neurosci21(15):5660–9.
56.
LongJMHoltzmanDM. 2019. Alzheimer disease: an update on pathobiology and treatment strategies. Cell179(2):312–39.
57.
LundgaardILuzhynskayaAStockleyJHWangZEvansKASwireM, and others. 2013. Neuregulin and BDNF induce a switch to NMDA receptor-dependent myelination by oligodendrocytes. PLoS Biol11(12):e1001743.
58.
LuoXHeWHuXYanR.2014. Reversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in mice. Biol Psychiatry76(2):120–7.
59.
MaHLesneSKotilinekLSteidl-NicholsJVShermanMYounkinL, and others. 2007. Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc Natl Acad Sci U S A104(19):8167–72.
60.
MarballiKCruzDThompsonPWalss-BassC.2012. Differential neuregulin 1 cleavage in the prefrontal cortex and hippocampus in schizophrenia and bipolar disorder: preliminary findings. PLoS One7(5):e36431.
61.
MarcinkiewiczMSeidahNG. 2000. Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. J Neurochem75(5):2133–43.
62.
MarquerCDevaugesVCossecJCLiotGLecartSSaudouF, and others. 2011. Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J25(4):1295–305.
63.
McCleanPLParthsarathyVFaivreEHolscherC.2011. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci31(17):6587–94.
64.
MiyamotoYToriiTTanoueAKawaharaKAraiMTsumuraH, and others. 2017. Neuregulin-1 type III knockout mice exhibit delayed migration of Schwann cell precursors. Biochem Biophys Res Commun486(2):506–513.
65.
NichollsDG. 1994. Proteins, transmitters, and synapses. Boston: Blackwell Scientific.
66.
NikolaevAMcLaughlinTO’LearyDDTessier-LavigneM.2009. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature457(7232):981–9.
67.
NolanCJPrentkiM.2019. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: time for a conceptual framework shift. Diab Vasc Dis Res16(2):118–27.
68.
OvsepianSVAntyborzecIO’LearyVBZaborszkyLHermsJOliver DollyJ.2014. Neurotrophin receptor p75 mediates the uptake of the amyloid beta (Aβ) peptide, guiding it to lysosomes for degradation in basal forebrain cholinergic neurons. Brain Struct Funct219(5):1527–41.
69.
OvsepianSVO’LearyVBZaborszkyLNtziachristosVDollyJO. 2018. Synaptic vesicle cycle and amyloid beta: Biting the hand that feeds. Alzheimers Dement14(4):502-513.
70.
OvsepianSVO’LearyVBZaborszkyLNtziachristosVDollyJO. 2019. Amyloid plaques of Alzheimer’s disease as hotspots of glutamatergic activity. Neuroscientist25:288–97.
71.
OzakiMSasnerMYanoRLuHSBuonannoA.1997. Neuregulin-beta induces expression of an NMDA-receptor subunit. Nature390(6661):691–4.
72.
PanzaFLozuponeMLogroscinoGImbimboBP. 2019. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol15(2):73–88.
73.
RennerMLacorPNVelascoPTXuJAContractorAKleinWL, and others. 2010. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron66(5):739–54.
74.
RieffHIRaetzmanLTSappDWYehHHSiegelRECorfasG.1999. Neuregulin induces GABAA receptor subunit expression and neurite outgrowth in cerebellar granule cells. J Neurosci19(24):10757–66.
75.
SavonenkoAVMelnikovaTLairdFMStewartKAPriceDLWongPC. 2008. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A105(14):5585–90.
76.
SelkoeDJ. 2002. Alzheimer’s disease is a synaptic failure. Science298(5594):789–91.
77.
SelkoeDJ. 2003. Aging, amyloid, and Alzheimer’s disease: a perspective in honor of Carl Cotman. Neurochem Res28(11):1705–13.
78.
ShankarGMBloodgoodBLTownsendMWalshDMSelkoeDJSabatiniBL. 2007. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci27(11):2866–75.
79.
ShimizuHTosakiAKanekoKHisanoTSakuraiTNukinaN.2008. Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production. Mol Cell Biol28(11):3663–71.
80.
SinhaSAndersonJPBarbourRBasiGSCaccavelloRDavisD, and others. 1999. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature402(6761):537–40.
81.
SnyderEMNongYAlmeidaCGPaulSMoranTChoiEY, and others. 2005. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci8(8):1051–8.
82.
StedehouderJKushnerSA. 2017. Myelination of parvalbumin interneurons: a parsimonious locus of pathophysiological convergence in schizophrenia. Mol Psychiatry22(1):4–12.
83.
TaveggiaCZanazziGPetrylakAYanoHRosenbluthJEinheberS, and others. 2005. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron47(5):681–94.
84.
VassarRBennettBDBabu-KhanSKahnSMendiazEADenisP, and others. 1999. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science286(5440):735–41.
85.
VassarRKovacsDMYanRWongPC. 2009. The beta-secretase enzyme BACE in health and Alzheimer’s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci29(41):12787–94.
86.
von ArnimCAKinoshitaAPeltanIDTangrediMMHerlLLeeBM, and others. 2005. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem280(18):17777–85.
87.
VullhorstDAhmadTKaravanovaIKeatingCBuonannoA.2017. Structural similarities between neuregulin 1-3 isoforms determine their subcellular distribution and signaling mode in central neurons. J Neurosci37(21):5232–49.
88.
WangHBLiRNShenY.2013. β-Secretase: its biology as a therapeutic target in diseases. Trends Pharmacol Sci34(4):215–25.
89.
WatersJ. 2010. The concentration of soluble extracellular amyloid-beta protein in acute brain slices from CRND8 mice. PLoS One5(12):e15709.
90.
WestmeyerGGWillemMLichtenthalerSFLurmanGMulthaupGAssfalg-MachleidtI, and others. 2004. Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme. J Biol Chem279(51):53205–12.
91.
WilcoxG. 2005. Insulin and insulin resistance. Clin Biochem Rev26(2):19–39.
92.
WillemMTahirovicSBuscheMAOvsepianSVChafaiMKootarS, and others. 2015. η-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature526(7573):443–7.
93.
YanRBienkowskiMJShuckMEMiaoHToryMCPauleyAM, and others. 1999. Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity. Nature402(6761):533–7.
94.
YanRHanPMiaoHGreengardPXuH.2001. The transmembrane domain of the Alzheimer’s beta-secretase (BACE1) determines its late Golgi localization and access to beta-amyloid precursor protein (APP) substrate. J Biol Chem276(39):36788–96.
95.
YanRMunznerJBShuckMEBienkowskiMJ. 2001. BACE2 functions as an alternative alpha-secretase in cells. J Biol Chem276(36):34019–27.
ZhuKPetersFFilserSHermsJ.2018. Consequences of pharmacological BACE inhibition on synaptic structure and function. Biol Psychiatry84(7):478–87.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
